PMID- 17656372
OWN - NLM
STAT- MEDLINE
DCOM- 20071220
LR  - 20131121
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 16
IP  - 22
DP  - 2007 Nov 15
TI  - Preservation of gray matter volume in multiple sclerosis patients with the Met 
      allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor.
PG  - 2659-68
AB  - To investigate the association of the rs6265 (Val66Met) single nucleotide 
      polymorphism (SNP) of brain-derived neurotrophic factor (BDNF) with brain 
      morphometry and functional status as measured by quantitative magnetic resonance 
      imaging (MRI) and neurocognitive testing in multiple sclerosis (MS) patients. 
      BDNF is released by neurons and by immune cells in MS brain. The rs6265 SNP 
      variation of BDNF causes substitution of valine (Val) for methionine (Met) and 
      interferes with activity-dependent BDNF secretion. A total of 209 treated MS 
      patients (161 females; 48 males) underwent clinical brain MRI and were genotyped 
      for the BDNF rs6265 Val66Met SNP. A subset of 108 patients had neurocognitive 
      testing for processing speed, memory and executive function. The MRI measurements 
      included T2 and T1-lesion volume (LV); normalized brain volume measures of whole 
      brain (WB) volume, white and gray matter volume (NWMV and NGMV) and the 
      diffusion-weighted imaging measure of WB mean parenchyma diffusivity (MPD). The 
      Met66 allele status was positively associated with NGMV (P = 0.015, standardized 
      beta = 0.15) and negatively associated with T2-LV (P = 0.041, standardized beta = 
      -0.14). There were no significant associations between Met66 allele status and 
      T1-LV, NWMV or MPD. On the Paced Serial Addition Test (PASAT), a trend (P = 
      0.057) favoring the Met66 allele group was observed. There were no significant 
      associations between Met66 allele status and other neurocognitive measures. The 
      BDNF Met66 allele is associated with lower damage as evidenced by measurement of 
      NGMV and T2-LV in MS patients.
FAU - Zivadinov, Robert
AU  - Zivadinov R
AD  - Buffalo Neuroimaging Analysis Center, Department of Neurology, State University 
      of New York, Buffalo, NY 14260, USA.
FAU - Weinstock-Guttman, Bianca
AU  - Weinstock-Guttman B
FAU - Benedict, Ralph
AU  - Benedict R
FAU - Tamano-Blanco, Miriam
AU  - Tamano-Blanco M
FAU - Hussein, Sara
AU  - Hussein S
FAU - Abdelrahman, Nadir
AU  - Abdelrahman N
FAU - Durfee, Jackie
AU  - Durfee J
FAU - Ramanathan, Murali
AU  - Ramanathan M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070726
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - AE28F7PNPL (Methionine)
SB  - IM
MH  - Brain/*pathology
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Methionine/*genetics
MH  - Middle Aged
MH  - Multiple Sclerosis/*genetics/metabolism
MH  - Neuropsychological Tests
MH  - *Polymorphism, Single Nucleotide
EDAT- 2007/07/28 09:00
MHDA- 2007/12/21 09:00
CRDT- 2007/07/28 09:00
PHST- 2007/07/28 09:00 [pubmed]
PHST- 2007/12/21 09:00 [medline]
PHST- 2007/07/28 09:00 [entrez]
AID - ddm189 [pii]
AID - 10.1093/hmg/ddm189 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2007 Nov 15;16(22):2659-68. doi: 10.1093/hmg/ddm189. Epub 2007 Jul 
      26.